Actavis

Fosaprepitant

Manufacturer:

Actavis

Fosaprepitant HCPCS:

J1456

HCPCS Code Descriptor:

Injection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg

Category:

J Code

Fosaprepitant NDCs:

00591-4385-79

Primary Type:

Oncology-Anti-Emetic

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Fosaprepitant:

Fosaprepitant is an Oncology-Anti-Emetic drug manufactured by Actavis and administered via the Intravenous route of administration. The J Code: J1456 is aligned to the drug Fosaprepitant.

ACCESS PRICING AND MORE BY REGISTERING

J1456 Added Date:

January 1, 2023

J1456 Effective Date:

January 1, 2023

J1456 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Fosaprepitant billing and coding information.
Our team did not identify a source for Fosaprepitant patient assistance information. Please reach out to our team if you feel that this is a mistake.
Fosaprepitant prescribing information can be found at the link below:
Information regarding Fosaprepitant’s side effects can be found at MedlinePlus